Assessment of factors that contribute to decreased quality of life in gynecologic oncology group ovarian cancer trials

Cancer

Volumn 115, Issue 20, 2009, Pages 4857-4864

  Von Gruenigen, Vivian E ^a   Huang, Helen Q ^b   Gil, Karen M ^c,d   Gibbons, Heidi E ^a   Monk, Bradley J ^e   Rose, Peter G ^f   Armstrong, Deborah K ^g   Cella, David ^h   Wenzel, Lari ⁱ  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c AKRON GENERAL MEDICAL CENTER   (United States)

^d Northeastern Ohio Medical University   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical interventions; Functional Assessment of Cancer Therapy; Psychosocial support; Quality of life domains; Symptom management

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMOTIONALITY; FEMALE; HUMAN; ILLNESS BEHAVIOR; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVARY CANCER; PAIN; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOCIAL WELFARE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANXIETY; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; OVARIAN NEOPLASMS; PACLITAXEL; QUALITY OF LIFE; SOCIAL SUPPORT;

EID: 70350090175     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24520     Document Type: Article

References (21)

1. von Gruenigen VE, Frasure HE, Grandon M, et al. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol. 2006;103:120-126. (Pubitemid 44374676)
2. Wenzel L, Huang HQ, Monk BJ, et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:5605-5612. (Pubitemid 46300155)
3. Chase DM, Monk BJ, Wenzel LB, et al. Supportive care for women with gynecologic cancers. Expert Rev Anticancer Ther. 2008;8:227-241.
4. Kearney N, Miller M, Maguire R, et al. Results of a European study of a nursing intervention for the management of chemotherapy-related symptoms. Eur J Oncol Nurs. 2008;12:443-448.
5. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol. 2007;5(2 suppl 1):5-12. (Pubitemid 46344212)
6. Lachaine J, Yelle L, Kaizer L, et al. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther. 2005;2:181-187.
7. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13:219-227.
8. Hsieh CC, Sprod LK, Hydock DS, et al. Effects of a supervised exercise intervention on recovery from treatment regimens in breast cancer survivors. Oncol Nurs Forum. 2008;35:909-915.
9. Wenzel LB, Huang HQ, Armstrong DK, et al. Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:437-443.
10. Armstrong DK, Bundy B, Wenzel L, et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med. 2006;54:34-43.
11. Rose PG, Nerenstone S, Brandy MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351:2489-2497. (Pubitemid 39603156)
12. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy (FACT) Scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579. (Pubitemid 23071057)
13. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation [serial online]. Health Qual Life Outcomes. 2003;1:79. (Pubitemid 39111917)
14. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. J Clin Oncol. 2001;19:1809-1817. (Pubitemid 32230884)
15. Fairclough DL, Cella DF. Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res. 1996;5:321-329.
16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
17. Liavaag AH, Dorum A, Fossa SD, et al. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol. 2007;25:2049-2056.
18. Mock V, Atkinson A, Barsevick AM, et al. Cancer-related fatigue: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5:1054-1078. (Pubitemid 350247713)
19. Dy SM, Lorenz KA, Naeim A, Sanati H, Walling A, Asch SM. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol. 2008;26:3886-3895.
20. Carmack Taylor CL, Basen-Engquist K, Shinn EH, et al. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol. 2004;22:881-889. (Pubitemid 41103600)
21. Wenzel LB, Donnelly JP, Fowler J, et al. Resilience, reflection and residual stress in ovarian cancer survivorship: a Gynecologic Oncology Group study. Psychooncology. 2002;11:142-153. (Pubitemid 34256425)